BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

406 related articles for article (PubMed ID: 10430032)

  • 1. Localization of rat cathepsin K in osteoclasts and resorption pits: inhibition of bone resorption and cathepsin K-activity by peptidyl vinyl sulfones.
    Xia L; Kilb J; Wex H; Li Z; Lipyansky A; Breuil V; Stein L; Palmer JT; Dempster DW; Brömme D
    Biol Chem; 1999 Jun; 380(6):679-87. PubMed ID: 10430032
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Osteoclastic bone degradation and the role of different cysteine proteinases and matrix metalloproteinases: differences between calvaria and long bone.
    Everts V; Korper W; Hoeben KA; Jansen ID; Bromme D; Cleutjens KB; Heeneman S; Peters C; Reinheckel T; Saftig P; Beertsen W
    J Bone Miner Res; 2006 Sep; 21(9):1399-408. PubMed ID: 16939398
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A highly potent inhibitor of cathepsin K (relacatib) reduces biomarkers of bone resorption both in vitro and in an acute model of elevated bone turnover in vivo in monkeys.
    Kumar S; Dare L; Vasko-Moser JA; James IE; Blake SM; Rickard DJ; Hwang SM; Tomaszek T; Yamashita DS; Marquis RW; Oh H; Jeong JU; Veber DF; Gowen M; Lark MW; Stroup G
    Bone; 2007 Jan; 40(1):122-31. PubMed ID: 16962401
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cystatin B as an intracellular modulator of bone resorption.
    Laitala-Leinonen T; Rinne R; Saukko P; Väänänen HK; Rinne A
    Matrix Biol; 2006 Apr; 25(3):149-57. PubMed ID: 16321512
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Different cysteine proteinases involved in bone resorption and osteoclast formation.
    Brage M; Abrahamson M; Lindström V; Grubb A; Lerner UH
    Calcif Tissue Int; 2005 Jun; 76(6):439-47. PubMed ID: 15906014
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Peptide aldehyde inhibitors of cathepsin K inhibit bone resorption both in vitro and in vivo.
    Votta BJ; Levy MA; Badger A; Bradbeer J; Dodds RA; James IE; Thompson S; Bossard MJ; Carr T; Connor JR; Tomaszek TA; Szewczuk L; Drake FH; Veber DF; Gowen M
    J Bone Miner Res; 1997 Sep; 12(9):1396-406. PubMed ID: 9286755
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potent and selective inhibition of human cathepsin K leads to inhibition of bone resorption in vivo in a nonhuman primate.
    Stroup GB; Lark MW; Veber DF; Bhattacharyya A; Blake S; Dare LC; Erhard KF; Hoffman SJ; James IE; Marquis RW; Ru Y; Vasko-Moser JA; Smith BR; Tomaszek T; Gowen M
    J Bone Miner Res; 2001 Oct; 16(10):1739-46. PubMed ID: 11585335
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structure-based development of pyridoxal propionate derivatives as specific inhibitors of cathepsin K in vitro and in vivo.
    Katunuma N; Matsui A; Inubushi T; Murata E; Kakegawa H; Ohba Y; Turk D; Turk V; Tada Y; Asao T
    Biochem Biophys Res Commun; 2000 Jan; 267(3):850-4. PubMed ID: 10673380
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overexpression of cathepsin K accelerates the resorption cycle and osteoblast differentiation in vitro.
    Morko J; Kiviranta R; Mulari MT; Ivaska KK; Väänänen HK; Vuorio E; Laitala-Leinonen T
    Bone; 2009 Apr; 44(4):717-28. PubMed ID: 19118660
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of Ulmus davidiana Planch (Ulmaceae) on bone resorption mediated by processing of cathepsin K in cultured mouse osteoclasts.
    Kim KW; Park JS; Kim KS; Jin UH; Kim JK; Suh SJ; Kim CH
    Phytother Res; 2008 Apr; 22(4):511-7. PubMed ID: 18338784
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Localisation and activity of cathepsins K and B in equine osteoclasts.
    Gray AW; Davies ME; Jeffcott LB
    Res Vet Sci; 2002 Apr; 72(2):95-103. PubMed ID: 12027589
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human osteoclast cathepsin K is processed intracellularly prior to attachment and bone resorption.
    Dodds RA; James IE; Rieman D; Ahern R; Hwang SM; Connor JR; Thompson SD; Veber DF; Drake FH; Holmes S; Lark MW; Gowen M
    J Bone Miner Res; 2001 Mar; 16(3):478-86. PubMed ID: 11277265
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The resorptive apparatus of osteoclasts supports lysosomotropism and increases potency of basic versus non-basic inhibitors of cathepsin K.
    Fuller K; Lindstrom E; Edlund M; Henderson I; Grabowska U; Szewczyk KA; Moss R; Samuelsson B; Chambers TJ
    Bone; 2010 May; 46(5):1400-7. PubMed ID: 20097319
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of bone resorption by selective inactivators of cysteine proteinases.
    Hill PA; Buttle DJ; Jones SJ; Boyde A; Murata M; Reynolds JJ; Meikle MC
    J Cell Biochem; 1994 Sep; 56(1):118-30. PubMed ID: 7806585
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Specific biological functions of vacuolar-type H(+)-ATPase and lysosomal cysteine proteinase, cathepsin K, in osteoclasts.
    Sahara T; Itoh K; Debari K; Sasaki T
    Anat Rec A Discov Mol Cell Evol Biol; 2003 Feb; 270(2):152-61. PubMed ID: 12524690
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An orally active cathepsin K inhibitor, furan-2-carboxylic acid, 1-{1-[4-fluoro-2-(2-oxo-pyrrolidin-1-yl)-phenyl]-3-oxo-piperidin-4-ylcarbamoyl}-cyclohexyl)-amide (OST-4077), inhibits osteoclast activity in vitro and bone loss in ovariectomized rats.
    Kim MK; Kim HD; Park JH; Lim JI; Yang JS; Kwak WY; Sung SY; Kim HJ; Kim SH; Lee CH; Shim JY; Bae MH; Shin YA; Huh Y; Han TD; Chong W; Choi H; Ahn BN; Yang SO; Son MH
    J Pharmacol Exp Ther; 2006 Aug; 318(2):555-62. PubMed ID: 16699068
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A potent small molecule, nonpeptide inhibitor of cathepsin K (SB 331750) prevents bone matrix resorption in the ovariectomized rat.
    Lark MW; Stroup GB; James IE; Dodds RA; Hwang SM; Blake SM; Lechowska BA; Hoffman SJ; Smith BR; Kapadia R; Liang X; Erhard K; Ru Y; Dong X; Marquis RW; Veber D; Gowen M
    Bone; 2002 May; 30(5):746-53. PubMed ID: 11996914
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recent advances in the ultrastructural assessment of osteoclastic resorptive functions.
    Sasaki T
    Microsc Res Tech; 1996 Feb; 33(2):182-91. PubMed ID: 8845517
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design of potent, selective, and orally bioavailable inhibitors of cysteine protease cathepsin k.
    Tavares FX; Boncek V; Deaton DN; Hassell AM; Long ST; Miller AB; Payne AA; Miller LR; Shewchuk LM; Wells-Knecht K; Willard DH; Wright LL; Zhou HQ
    J Med Chem; 2004 Jan; 47(3):588-99. PubMed ID: 14736240
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of molecules in mother-of-pearl on the decrease in bone resorption through the inhibition of osteoclast cathepsin K.
    Duplat D; Gallet M; Berland S; Marie A; Dubost L; Rousseau M; Kamel S; Milet C; Brazier M; Lopez E; Bédouet L
    Biomaterials; 2007 Nov; 28(32):4769-78. PubMed ID: 17686515
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.